AHF: CDC Again Fails to Mention Condoms in Latest HIV Prevention Campaign or Role in 18% Decline in Infections

AIDS Healthcare Foundation (AHF) welcomed the news last week of an 18% decline in HIV infections in the United States between 2008 and 2014, but is questioning some of the conclusions drawn by Centers for Disease Control and Prevention (CDC) officials regarding the role of pre-exposure prophylaxis (PrEP), in particular, in the decline.

In addition, AHF chastised the CDC for overlooking the role that condoms may have played in the decline and blasted the organization for failing to even mention or include condom use in the roll out, and as part of its new ‘HIP’ (High-impact Prevention) approach to HIV prevention, which includes HIV testing, treatment-as-prevention, needle exchange and PrEP, but no mention of condoms.

In a CDC press release issued last week timed to coincide with the annual Conference on Retroviruses and Opportunistic Infections (CROI) held in Seattle, (“New HIV infections drop 18 percent in six years” February 14, 2017), CDC officials rightly tagged treatment-as-prevention as a likely contributor to the welcome decline in infections, noting:

“CDC researchers believe the declines in annual HIV infections are due, in large part, to efforts to increase the number of people living with HIV who know their HIV status and are virally suppressed – meaning their HIV infection is under control through effective treatment. This is a top public health priority. Studies have shown that, in addition to improving the health of people living with HIV, early treatment with antiretroviral medications dramatically reduces a person’s risk of transmitting the virus to others.”

However, AHF officials believe that the CDC was on far shakier ground when it claimed, “Increases in the use of pre-exposure prophylaxis, or PrEP, may also have played a role in preventing new infections in recent years.”

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below